Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System.

Kang, Dong Hyuk; Lee, Joo Yong; Lee, Yunhee; Ha, U-Syn

Kang, Dong Hyuk; Lee, Joo Yong; Lee, Yunhee; Ha, U-Syn.

Afiliação

Kang DH; Department of Urology, Inha University College of Medicine, Incheon, Korea.
Lee JY; Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Lee Y; Center of Evidence Based Medicine, Institute of Convergence Science, Yonsei University, Seoul, Korea.
Ha US; Department of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-Daero, Seocho-Gu, Seoul, 06591, Korea.

BMC Cancer ; 23(1): 483, 2023 May 30.

Article em En | MEDLINE | ID: mdl-37254112

Assuntos

Antineoplásicos; Carcinoma de Células Renais; Neoplasias Renais; Humanos; Carcinoma de Células Renais/tratamento farmacológico; Carcinoma de Células Renais/genética; Neoplasias Renais/tratamento farmacológico; Neoplasias Renais/genética; Sunitinibe/uso terapêutico; Axitinibe/uso terapêutico; República da Coreia/epidemiologia; Antineoplásicos/uso terapêutico

Palavras-chave

Axitinib; Cabozantinib; Pazopanib; Renal cell carcinoma; Sunitinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Limite: Humans País/Região como assunto: Asia Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google